Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + oxaliplatin + capecitabine
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
The combination of docetaxel, oxaliplatin, and capecitabine is a chemotherapy regimen used primarily for the treatment of advanced gastric cancer. This triplet therapy is sometimes referred to as the TEX or DOC regimen. Docetaxel is a taxane that inhibits microtubule depolymerization and disrupts cell division. Oxaliplatin is a platinum-based agent that forms DNA crosslinks and induces apoptosis in rapidly dividing cells. Capecitabine is an oral prodrug converted to 5-fluorouracil (5-FU) in the body; it inhibits thymidylate synthase and interferes with DNA synthesis. Together, these agents target different aspects of cancer cell proliferation and survival[1][4][6][8]. The combination has shown activity as first-line therapy for metastatic or advanced gastric cancer with manageable toxicity profiles.
- Brand names
- EloxatinTaxotereXeloda
- Other names
- docetaxel/oxaliplatin/capecitabineDOC regimenTEX regimen
02
Targets
TS (Thymidylate synthase)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on docetaxel + oxaliplatin + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + oxaliplatin + capecitabine.